Literature DB >> 17079331

Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation.

Lisa M Nilsson1, Zheng-Wu Sun, Jenny Nilsson, Ina Nordström, Yung-Wu Chen, Jeffery D Molkentin, Dag Wide-Swensson, Per Hellstrand, Marie-Louise Lydrup, Maria F Gomez.   

Abstract

The calcineurin/nuclear factor of activated T cells (NFAT) signaling pathway has been found to play a role in regulating growth and differentiation in several cell types. However, the functional significance of NFAT in the vasculature is largely unclear. Here we show that NFATc1, NFATc3, and NFATc4 are expressed in human myometrial arteries. Confocal immunofluorescence and Western blot analysis revealed that endothelin-1 efficiently increases NFATc3 nuclear accumulation in native arteries. Endothelin-1 also stimulates NFAT-dependent transcriptional activity, as shown by a luciferase reporter assay. Both the agonist-induced NFAT nuclear accumulation and transcriptional activity were prevented by the calcineurin inhibitor CsA and by the novel NFAT blocker A-285222. Chronic inhibition of NFAT significantly reduced IL-6 production in intact myometrial arteries and inhibited cell proliferation in vascular smooth muscle cells cultured from explants from the same arteries. Furthermore, by using small interfering RNA-mediated reduction of NFATc3, we show that this isoform is involved in the regulation of cell proliferation. Protein synthesis in intact arteries was investigated using autoradiography of [(35)S]methionine incorporation in serum-free culture. Inhibition of NFAT signaling did not affect overall protein synthesis or specifically the synthesis rates of major proteins associated with the contractile/cytoskeletal system. An intact contractile phenotype under these conditions was also shown by unchanged force response to depolarization or agonist stimulation. Our results demonstrate NFAT expression and activation in native human vessels and point out A-285222 as a powerful pharmacological blocker of NFAT signaling in the vasculature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079331     DOI: 10.1152/ajpcell.00590.2005

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  44 in total

1.  TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription.

Authors:  Johannes Schlöndorff; Donato Del Camino; Robert Carrasquillo; Vanessa Lacey; Martin R Pollak
Journal:  Am J Physiol Cell Physiol       Date:  2009-01-07       Impact factor: 4.249

2.  NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.

Authors:  Sergio de Frutos; Elizabeth Caldwell; Carlos H Nitta; Nancy L Kanagy; Jian Wang; Wei Wang; Mary K Walker; Laura V Gonzalez Bosc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-21       Impact factor: 4.733

Review 3.  Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis.

Authors:  Anthony Wayne Orr; Nicole E Hastings; Brett R Blackman; Brian R Wamhoff
Journal:  J Vasc Res       Date:  2009-10-22       Impact factor: 1.934

4.  RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.

Authors:  Jolyane Meloche; Roxane Paulin; Audrey Courboulin; Caroline Lambert; Marjorie Barrier; Pierre Bonnet; Malik Bisserier; Mélanie Roy; Mark A Sussman; Mohsen Agharazii; Sébastien Bonnet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-16       Impact factor: 8.311

Review 5.  Targeting angiogenesis and the tumor microenvironment.

Authors:  Jennifer Samples; Monte Willis; Nancy Klauber-Demore
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

6.  Cyclosporine up-regulates Krüppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo.

Authors:  Sean M Garvey; Daniel S Sinden; Pamela D Schoppee Bortz; Brian R Wamhoff
Journal:  J Pharmacol Exp Ther       Date:  2010-01-20       Impact factor: 4.030

7.  Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia.

Authors:  Lisa M Nilsson-Berglund; Anna V Zetterqvist; Jenny Nilsson-Ohman; Mikael Sigvardsson; Laura V González Bosc; Maj-Lis Smith; Albert Salehi; Elisabet Agardh; Gunilla Nordin Fredrikson; Carl-David Agardh; Jan Nilsson; Brian R Wamhoff; Anna Hultgårdh-Nilsson; Maria F Gomez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

8.  NFATc3 is required for intermittent hypoxia-induced hypertension.

Authors:  Sergio de Frutos; Laura Duling; Dominique Alò; Tammy Berry; Olan Jackson-Weaver; Mary Walker; Nancy Kanagy; Laura González Bosc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-03-21       Impact factor: 4.733

9.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

10.  Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.

Authors:  Cong Wang; Ji-Feng Li; Lan Zhao; Jie Liu; Jun Wan; Yue Xiu Wang; Jun Wang; Chen Wang
Journal:  Respir Res       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.